Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsSafety and efficacy of azacitidine in myelodysplastic syndromesAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsDecitabine in the treatment of myelodysplastic syndromesMonitoring the effect of belinostat in solid tumors by H4 acetylationEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsUpdate on rational targeted therapy in AMLMolecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric DisordersNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatmentsNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeChildhood acute myeloid leukaemiaPredicting response to epigenetic therapyFeasibility of therapy with hypomethylating agents in patients with renal insufficiencyHydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trialMechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemiaHistone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaIntegrative modeling of multi-platform genomic data under the framework of mediation analysis.A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).Decitabine: a review of its use in older patients with acute myeloid leukaemia.Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reportsMyelodysplastic syndromes: Contemporary review and how we treat.Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndromePhase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.Large-scale analysis of DNA methylation in chronic lymphocytic leukemiaDNA hypomethylation in cancer cells.Epigenetic therapies in MDS and AMLChanges in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancerCase series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsA phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
P2860
Q21198868-EE76E247-95F5-45A1-9AEF-2194B038EC63Q24596561-1F9258D4-30AC-4752-A9AC-7A43D8E3172BQ24622700-3FCB7773-D46A-4C84-B64B-1C274AE957DCQ24633763-5AB1D926-4934-428D-954C-C22D0161E3EEQ24641906-2974366D-9B03-4DA5-8F90-3B99CB657ACEQ24644030-F27DC605-B5DC-44DE-8E56-212B91A75E75Q26744080-FBE592E0-8F2D-4BD6-9341-31AA66E95D98Q26749421-7C499725-8B6C-43A2-A091-DF6F635D86B4Q26766152-B15EC71E-CDF8-486E-B5BC-6B282907AAA7Q26766487-6B7D18C9-11B6-499C-856B-7582F9F2E671Q26770391-3B7AAA10-3FA2-4CEA-8DE1-CA1B5F96F4C3Q26828724-69D2F1D0-64F4-4961-899A-095FB441C26DQ26829132-585EFD99-7C73-4D13-91D4-93FBEDC72122Q27005960-2BEE8289-36CF-4D1C-A819-CA2B12370A04Q27027751-0301DC48-E5F5-427F-BB1A-0F9A8E678297Q28283836-84F97585-A265-4AC6-8DF7-C744E41BED14Q28294892-4B94D619-69AE-480F-8989-B0CDD3376DCAQ28385690-1B0AE7BC-41D3-4829-9AE6-291083478305Q29394054-58EF3B89-D176-4404-BF94-C297173E6FC5Q30860315-9A328998-5162-4246-A868-AD79BB9BFAB7Q33267359-E73435A3-2D26-4D95-9BCE-E9AE15B3EFDBQ33393266-BDD79992-DFDA-4787-9D10-8EE0EC825FE4Q33395173-4AFD5F55-9CF5-4778-9F27-76F3AF5BB359Q33407030-D90D4346-DCC4-49C3-90B3-8346F3747BD0Q33407141-AFC8A6D3-5883-4F4E-B122-08A3BFF4FDBBQ33429195-745A2D27-20EC-449B-ADD7-1143F3388733Q33558088-D343C5C3-8BEE-4A26-80E2-F18FCE629921Q33665187-A703263C-1F55-4000-91D7-68A348EE0B25Q33741025-4F361580-07DF-489A-A26B-E1E86496EE14Q33775647-0E79FBDA-B1CB-4A53-9962-9367C4D6D7A8Q33841988-9E3ED11F-EC45-4F40-8C36-8711224B478FQ33843955-041EA8ED-BFBF-4B0D-92CF-4399BDB45576Q33844751-8F4DE408-D810-454F-9D1F-709215EC80B2Q33847891-3148A9A2-3EEC-450F-AC30-56895A0CB3D8Q33859881-069A2886-4627-4ED2-A3A3-8B0DE6DC333AQ33862334-ACB65752-F8CE-4D78-9C8A-B14C62F43C2AQ33863567-EEA6AD07-820D-492D-8C91-4950786F399CQ33863925-A9E65AD8-0AC7-4D7B-A54A-C6D714CB0276Q33929924-0A12B591-B681-4102-8A43-6D92B261EE4DQ33939624-4E00DCE1-D4DC-43EA-8D9E-D861B6BB8B6A
P2860
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@ast
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@en
type
label
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@ast
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@en
prefLabel
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@ast
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@en
P2093
P2860
P50
P1433
P1476
Phase 1/2 study of the combina ...... cid in patients with leukemia.
@en
P2093
Blanca Sanchez-Gonzalez
Carlos Bueso-Ramos
Charles Koller
Elihu Estey
Gary Rosner
Jackie Fiorentino
Jean-Pierre Issa
Lianchun Xiao
Michael Rytting
P2860
P304
P356
10.1182/BLOOD-2006-03-009142
P407
P50
P577
2006-08-01T00:00:00Z